Retrophin, Inc. is a company in the U.S. stock market and it is a holding in 34 U.S.-traded ETFs. RTRX has around 4.3M shares in the U.S. ETF market. The largest ETF holder of RTRX is the SPDR S&P Biotech ETF (XBI), with approximately 1.01M shares. Investors may also find of interest that the ETF with the largest allocation to RTRX stock is Invesco Dynamic Pharmaceuticals ETF (PJP), with a portfolio weight of 2.81%. On average, U.S. ETFs allocate 0.22% of RTRX to their portfolios.
Additionally, RTRX is a favorite stock for Vanilla and Multi-factor ETFs. It is also most likely to belong to Broad-based ETFs. The best-performing ETF in the past 12 months with RTRX as a holding is the ProShares Ultra NASDAQ Biotechnology (BIB), with a return of 40.81%.